» Articles » PMID: 26109954

MicroRNA-124 Slows Down the Progression of Huntington's Disease by Promoting Neurogenesis in the Striatum

Overview
Date 2015 Jun 26
PMID 26109954
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA-124 contributes to neurogenesis through regulating its targets, but its expression both in the brain of Huntington's disease mouse models and patients is decreased. However, the effects of microRNA-124 on the progression of Huntington's disease have not been reported. Results from this study showed that microRNA-124 increased the latency to fall for each R6/2 Huntington's disease transgenic mouse in the rotarod test. 5-Bromo-2'-deoxyuridine (BrdU) staining of the striatum shows an increase in neurogenesis. In addition, brain-derived neurotrophic factor and peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein levels in the striatum were increased and SRY-related HMG box transcription factor 9 protein level was decreased. These findings suggest that microRNA-124 slows down the progression of Huntington's disease possibly through its important role in neuronal differentiation and survival.

Citing Articles

The Role of MicroRNAs in Neurodegeneration: Insights from Huntington's Disease.

Mansour R, Shaker A, Abulsoud A, Mageed S, Ashraf A, Elsakka E Mol Neurobiol. 2025; .

PMID: 40009259 DOI: 10.1007/s12035-025-04750-7.


Polyphenols as Wnt/β-catenin pathway modulators: A promising strategy in clinical neurodegeneration.

Utpal B, Roy S, Zehravi M, Sweilam S, Raja A, Akiful Haque M Animal Model Exp Med. 2025; 8(2):266-286.

PMID: 39808166 PMC: 11871115. DOI: 10.1002/ame2.12525.


Exosome Cargo in Neurodegenerative Diseases: Leveraging Their Intercellular Communication Capabilities for Biomarker Discovery and Therapeutic Delivery.

Zhang S, Yang Y, Lv X, Zhou X, Zhao W, Meng L Brain Sci. 2024; 14(11).

PMID: 39595812 PMC: 11591915. DOI: 10.3390/brainsci14111049.


miR-124 coordinates metabolic regulators acting at early stages of human neurogenesis.

Son G, Na Y, Kim Y, Son J, Clemenson G, Schafer S Commun Biol. 2024; 7(1):1393.

PMID: 39455851 PMC: 11511827. DOI: 10.1038/s42003-024-07089-2.


Extracellular Vesicles: The Next Generation of Biomarkers and Treatment for Central Nervous System Diseases.

Zanirati G, Dos Santos P, Alcara A, Bruzzo F, Ghilardi I, Wietholter V Int J Mol Sci. 2024; 25(13).

PMID: 39000479 PMC: 11242541. DOI: 10.3390/ijms25137371.


References
1.
Johnson R, Zuccato C, Belyaev N, Guest D, Cattaneo E, Buckley N . A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis. 2007; 29(3):438-45. DOI: 10.1016/j.nbd.2007.11.001. View

2.
Akerblom M, Sachdeva R, Barde I, Verp S, Gentner B, Trono D . MicroRNA-124 is a subventricular zone neuronal fate determinant. J Neurosci. 2012; 32(26):8879-89. PMC: 4434222. DOI: 10.1523/JNEUROSCI.0558-12.2012. View

3.
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A . A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129(7):1401-14. PMC: 2681231. DOI: 10.1016/j.cell.2007.04.040. View

4.
Kocerha J, Xu Y, Prucha M, Zhao D, Chan A . microRNA-128a dysregulation in transgenic Huntington's disease monkeys. Mol Brain. 2014; 7:46. PMC: 4065582. DOI: 10.1186/1756-6606-7-46. View

5.
Tsunemi T, Ashe T, Morrison B, Soriano K, Au J, Roque R . PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med. 2012; 4(142):142ra97. PMC: 4096245. DOI: 10.1126/scitranslmed.3003799. View